Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis.

ABSTRACT:

Background

Treatment with aspirin and a P2Y12 inhibitor is commonly used in patients with cardiovascular disorders. The overall effect of such treatment on all-cause mortality is unknown. In the Dual Antiplatelet Therapy (DAPT) Study, continuation of dual antiplatelet therapy beyond 12 months after coronary stenting was associated with an unexpected increase in non-cardiovascular death. In view of the potential public health importance of these findings, we aimed to assess the effect of extended duration dual antiplatelet therapy on mortality by doing a meta-analysis of all randomised, controlled trials of treatment duration in various cardiovascular disorders.

Methods

We searched Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) to identify rando

SUBMITTER: Elmariah S 

PROVIDER: S-EPMC4386690 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature